The New Low Calcemic Vitamin D Analog 22-Ene-25-Oxa-Vitamin D Prominently Ameliorates T Helper Cell Type 1-Mediated Colitis in Mice

1st Department of Internal Medicine, Division of Gastroenterology and Clinical Nutrition, Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
Journal of Pharmacology and Experimental Therapeutics (Impact Factor: 3.97). 12/2006; 319(2):622-31. DOI: 10.1124/jpet.106.107599
Source: PubMed


In addition to its well defined role as a key regulator of calcium and bone metabolism, 1,25-dihydroxyvitamin D(3) (calcitriol) has been established as a potent modulator of immune cell function. Still, because of the hypercalcemic toxicity occurring after systemic application of the parent compound, its clinical application as an immunosuppressant has been hampered. Recently, we described 22-ene-25-oxa-vitamin D (ZK156979) as a representative of a novel class of low calcemic vitamin D analogs with well preserved immunosuppressive activity in vitro. Here, in vivo colitis was induced by applying a rectal enema of 2,4,6-trinitrobenzene sulfonic acid (TNBS) to male BALB/c mice, and calcitriol (0.2 microg/kg) or ZK156979 (0.1-2.0 microg/kg) was given i.p. from days 0 to 3 or 3 to 5. Body mass and clinical activity score of colitis were recorded daily. Colon tissue was analyzed macroscopically and microscopically, myeloperoxidase activity and cytokine levels [tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma, interleukin (IL)-10, and IL-4] were determined by enzyme-linked immunosorbent assay, and T-box transcription factor (T-bet) expression was determined by immunoblot analysis. We found that treatment with ZK156979 clearly reduced the severity of TNBS-induced colitis without exhibiting calcemic effects. Both early and late treatment abrogated body weight loss, diarrhea, and macroscopic intestinal inflammation with a potency comparable with that of calcitriol. The therapeutic effect of ZK156979 was accompanied by a down-regulation of myeloperoxidase activity, TNF-alpha, IFN-gamma, and T-bet expression decreased, whereas local tissue IL-10 and IL-4 protein levels increased. To conclude, our data provide the first clear evidence that ZK156979 exhibits a beneficial prophylactic as well as therapeutic profile in T helper cell type 1-like experimental colitis, offering new therapeutic options for the treatment of human inflammatory bowel diseases.

Download full-text


Available from: Heinfried H Radeke, Nov 11, 2014
17 Reads
  • Source
    • "By performing modifications in the side chain of 1,25-(OH) 2 D 3 , one group described the VDR agonist ZK156979 (22-ene-25-oxa- vitamin D), which at normocalcemic doses effectively improved the symptoms of colitis induced by 2,4,6- trinitrobenzene sulfonic acid by inhibiting TNFa production and increasing levels of anti-inflammatory cytokines. In vivo experiments performed in rats showed that ZK156979 exhibited 100-fold lower hypercalcemic activity than 1,25-(OH) 2 D 3 (Daniel et al., 2005, 2006). Use of another VDR analog, TX527 [19-nor-14,20- bisepi-23-yne-1,25(OH) 2 D 3 ], proved efficacious at inhibiting cell proliferation and TNFa production in vitro in human PBMCs from Crohn's disease patients (Stio et al., 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nuclear receptors are ligand-activated transcription factors and include the receptors for steroid hormones, lipophilic vitamins, sterols, and bile acids. These receptors serve as targets for development of myriad drugs that target a range of disorders. Classically defined ligands that bind to the ligand-binding domain of nuclear receptors, whether they are endogenous or synthetic, either activate receptor activity (agonists) or block activation (antagonists) and due to the ability to alter activity of the receptors are often termed receptor "modulators." The complex pharmacology of nuclear receptors has provided a class of ligands distinct from these simple modulators where ligands display agonist/partial agonist/antagonist function in a tissue or gene selective manner. This class of ligands is defined as selective modulators. Here, we review the development and pharmacology of a range of selective nuclear receptor modulators.
    Pharmacological reviews 02/2013; 65(2):710-78. DOI:10.1124/pr.112.006833 · 17.10 Impact Factor
  • Source
    • "Protein extracts from colon samples (obtained 2 and 4 cm above the anus and pooled), PBMCs, MM6 cells, and activated mesenteric lymph nodes (MLNs) were prepared by using a cell extraction kit (Active Motif Nuclear Extract Kit; Active Motif, Rixensart, Belgium) according to the instructions of the manufacturer and analyzed for protein content with bicinchoninic acid protein assay reagent (Thermo Fisher Scientific, Bonn, Germany). For SDS-polyacrylamide gel electrophoresis and Western blotting refer to the protocol described previously (Daniel et al., 2006). Visualization and quantification of protein bands were carried out with the Odyssey Infrared Imaging System (LI-COR Biosciences, Bad Homburg, Germany). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite being a mainstay of inflammatory bowel disease (IBD) therapy, glucocorticoids (GCs) still carry significant risks with respect to unwanted side effects. Alternative drugs with a more favorable risk/benefit ratio than common GCs are thus highly desirable for the management of IBD. New and supposedly selective glucocorticoid receptor (GR) agonists (SEGRAs), with dissociated properties, have been described as promising candidates for circumventing therapeutic problems while still displaying full beneficial anti-inflammatory potency. Here, we report on compound A [CpdA; (2-((4-acetophenyl)-2-chloro-N-methyl)ethylammonium-chloride)] and N-(4-methyl-1-oxo-1H-2,3-benzoxazine-6-yl)-4-(2,3-dihydrobenzofuran-7-yl)-2-hydroxy-2-(trifluoromethyl)-4-methylpentanamide (ZK216348), two GR agonists for the treatment of experimental colitis. Their therapeutic and anti-inflammatory effects were tested in the acute trinitrobenzene sulfonic acid-mediated colitis model in mice against dexamethasone (Dex). In addition to their influence on immunological pathways, a set of possible side effects, including impact on glucose homeostasis, steroid resistance, and induction of apoptosis, was surveyed. Our results showed that, comparable with Dex, treatment with CpdA and ZK216348 reduced the severity of wasting disease, macroscopic and microscopic damage, and colonic inflammation. However, both SEGRAs exhibited no GC-associated diabetogenic effects, hypothalamic pituitary adrenal axis suppression, or development of glucocorticoid resistance. In addition, CpdA and ZK216348 showed fewer transactivating properties and successfully dampened T helper 1 immune response. Unlike ZK216348, the therapeutic benefit of CpdA was lost at higher doses because of toxic apoptotic effects. In conclusion, both SEGRAs acted as potent anti-inflammatory agents with a significantly improved profile compared with classic GCs. Although CpdA revealed a narrow therapeutic window, both GR agonists might be seen as a starting point for a future IBD treatment option.
    Journal of Pharmacology and Experimental Therapeutics 01/2012; 341(1):68-80. DOI:10.1124/jpet.111.183947 · 3.97 Impact Factor
  • Source
    • "Amelioration of symptoms, block of disease progression Cantorna et al. (2000) Vitamin D deficiency Disease aggravation Cantorna et al. (2000) VDRÀ/Àmice Disease aggravation Froicu et al. (2003, 2006), Froicu and Cantorna, (2007) Colitis Treatment with an analog in mice anti-inflammatory effects -at least partially mediated through effects on mucosal DCs Daniel et al. (2006), Strauch et al., (2007) "
    [Show abstract] [Hide abstract]
    ABSTRACT: 1,25(OH)(2)D(3), the active form of vitamin D, is a central player in calcium and bone metabolism. More recently, important immunomodulatory effects have been attributed to this hormone. The widespread presence of the vitamin D receptor (VDR) in the immune system and the expression of the enzymes responsible for the synthesis of the active 1,25(OH)(2)D(3) regulated by specific immune signals, even suggest a paracrine immunomodulatory role for 1,25(OH)(2)D(3). Additionally, the different molecular mechanisms used by 1,25(OH)(2)D(3) to exert its immunomodulatory effects prove of a broad action radius for this compound. Both, the effects of vitamin D deficiency and/or absence of the VDR as well as intervention with pharmacological doses of 1,25(OH)(2)D(3) or one of its less-calcemic analogs, affects immune system behavior in different animal models of immune-mediated disorders, such as type 1 diabetes. This review aims to summarize the data as they stand at the present time on the role of vitamin D in the pathogenesis of immune-mediated disorders, with special focus on type 1 diabetes, and on the therapeutic opportunities for vitamin D in the prevention and treatment of this autoimmune disease in mouse models and humans.
    Molecular Aspects of Medicine 08/2008; 29(6):376-87. DOI:10.1016/j.mam.2008.05.004 · 10.24 Impact Factor
Show more